Tumor suppressor genes

Current Opinion in Genetics and Development

Volumn 10, Issue 1, 2000, Pages 81-93

  Macleod, Kay ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIN D1; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMAD PROTEIN;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; HETEROZYGOSITY LOSS; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0034002662     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(99)00041-6     Document Type: Review

References (108)

1. Knudson A.G. Antioncogenes and human cancer. Proc Natl Acad Sci USA. 90:1993;10914-10921.
2. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 68:1971;820-823.
3. Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K.V., Markowitz S.D., Kinzler K.W., Vogelstein B. Mutation of mitotic checkpoint genes in human cancer. Nature. 392:1998;300-303.
4. Markowitz S., Wang J., Myeroff L., Parsons R.P., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B.et al. Inactivation of type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
5. Hahn S.A., Schutte M., Hoque A.T.M.S., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353.
6. Zhu Y., Richardson J.A., Parada L.F., Graff J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:1998;703-714. Smad3 mutant mice die between 4 and 6 months of age with colorectal adenocarcinomas which have metastasised through the intestinal wall and to the lymph nodes. In contrast, mice mutant for other components of the TGF-β signaling pathway (Smad4, Smad 2, type II TGF-β receptor and TGF-β ligands) do not develop colorectal cancer in the heterozygous state and are embryonic lethal in the homozygous state. SMAD3, however, has not been found mutated in human colorectal cancer although LOH at 15q does occur in a subset of human tumors. Clearly Smad2 cannot compensate for Smad3 in protecting mouse colonic epithelium despite the high degree of homology that exists between them.
7. Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., Dyson N.J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85:1996;537-548.
8. Dietrich W.F., Lander E.S., Smith J.S., Moser A.R., Gould K.A., Luongo C., Borenstein N., Dove W.F. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell. 75:1993;631-639.
9. Shoemaker A.R., Gould K.A., Luongo C., Moser A.R., Dove W.F. Studies of neoplasia in the Min mouse. Biochimica et Biophyica Acta. 1332:1997;F25-F48.
10. Min mutation to promote tumorigenesis in the intestine, mammary and salivary glands. The authors suggest that Tcf-1 acts as a feedback repressor of β-catenin/Tcf-4 gene expression, explaining the apparent genetic interaction between Apc and Tcf-1 in tumorigenesis.
11. Kinzler K., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
12. Kinzler K.W., Vogelstein B. Landscaping the cancer terrain. Science. 280:1998;1036-1037.
13. Δ716 mice, suggesting that loss of Dpc4(Smad4) cooperated with Apc mutation in colorectal tumorigenesis.
14. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
15. Giaccia A.J., Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:1998;2973-2983.
16. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15-16.
17. Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G. PTEN germ-line mutations in juvenile polyposis coli. Nat Genet. 18:1998;12-14.
18. Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., Swisshelm K., Suchard D., Macleod P.M., Kvinnsland S.et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease and juvenile polyposis. Am J Hum Genet. 61:1997;1254-1260.
19. Howe J.R., Roth S., Ringold J.C., Summers R.W., Jarvinen H.J., Sistonen P., Tomlinson I.P.M., Houlston R.S., Bevan S., Mitros F.A.et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 280:1998;1086-1088.
20. Macleod K. pRb and E2f-1 in mouse development and tumorigenesis. Curr Opin Genet Dev. 9:1999;31-39.
21. KIP1 is haplo-insufficient for tumorigenesis.
22. Sherr M.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
23. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Firpo E., Polyak K., Tsai L.H., Broudy V., Perlmutter R.M.et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1 deficient mice. Cell. 85:1996;733-744.
24. Marsh D.J., Dahia P.L., Coulon V., Zheng Z., Dorion-Bonnet F., Call K.M., Little R., Lin A.Y., Eeles R.A., Goldstein A.M.et al. Allelic imbalance, including deletion of PTEN/MMAC1 at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syyndrome and germline PTEN mutations. Genes Chromosomes Cancer. 21:1998;61-69.
25. +/- mice were predisposed to intestinal polyposis, leukemia and teratomas.
26. -/- ES cells, the authors attribute a role to Pten in regulating normal differentiation and organisation of the germ layers.
27. +/- cells to respond to Fas, suggesting that the function of Pten in blocking Akt activity is the key to understanding the role of Pten in Fas signaling.
28. -/-cells show increased levels of Akt kinase activity. These observations suggest that Pten functions as a tumor suppressor by negatively regulating the PI3′-kinase/Akt signaling pathway.
29. Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B., Aaltonen L.A., de la Chappelle A., Spiegelman B.M., Eng C. Loss-of-function mutations in PPARγ associated with human cancer. Mol Cell. 3:1999;799-804. Point mutations in the ligand-inducible PPARγ nuclear receptor are found in sporadic colon cancer. These mutations affect the ability of PPARγ to activate transcription and induce differentiation. Loss of function of the wild-type allele was not detected, leading to the suggestion that mutant PPARγ acts as a dominant negative to inhibit activation of gene expression by wild-type PPARγ.
30. Venkatachalam S., Shi Y., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17:1998;4657-4667.
31. Kemp C.J., Donehower L.A., Bradley A., Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell. 74:1993;813-822.
32. Min mice frequently (30%) fail to show LOH in intestinal polyps. In contrast, on a C57BL/6J genetic background, all tumors tested show LOH. The level of Apc expression from the remaining wild-type allele is reduced, suggesting that transcriptional silencing effectively achieves LOH.
33. Cook D.L., Gerber A.N., Tapscott S.J. Modeling stochastic gene expression: implications for haploinsufficiency. Proc Natl Acad Sci USA. 95:1998;15641-15646. Gene expression patterns are modeled to explain how reduced gene copy number and expression rate can be critical to determining the outcome of heterozygosity at a given gene. It is predicted that diploid systems would be more resistant to the effects of stochastic changes in gene expression than haploid systems, providing an explanation for haplo-insufficiency syndromes.
34. +/- mice. Nat Genet. 18:1998;360-363.
35. Bhatia-Gour R., Donjacour A.A., Sciavolino P.J., Kim M., Desai N., Young P., Norton C.R., Gridley T., Cardiff R.D., Cunha G.R.et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13:1999;966-977. The Nkx3.1 gene product is an early marker of prostate epithelium differentiation and negatively regulates prostate epithelial proliferation. Mice heterozygous for Nkx3.1 show hyperplasia and dysplasia of the prostate epithelium in an age-dependent manner. LOH did not accompany tumor development. NKX3.1 maps to a prostate cancer hot spot on human chromosome 8p21. Over-expression of Nkx3.1 in prostate carcinoma cells blocks growth and suppressed tumorigenicity in culture.
36. +/- astrocytes is dependent on stromal interaction with neurons but does not require LOH at the Nf1 locus.
37. Goodrich L.V., Milenkovic L., Higgins K.M., Scott M.P. Altered neural fates and medulloblastoma in mouse patched mutants. Science. 277:1997;1109-1113.
38. Tang B., Bottinger E.P., Jakowlew S.B., Bagnall K.M., Mariano J., Anver M.R., Letterio J.J., Wakefield L.M. TGF-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med. 4:1998;802-807.
39. Chin L., Merlino G., DePinho R.A. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12:1998;3467-3481.
40. Dyson N. The regulation of E2F by pRB-family members. Genes Dev. 12:1998;2245-2262.
41. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
42. Lowe S.W., Jacks T., Housman D.E., Ruley H.E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA. 91:1994;2026-2030.
43. Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S., Jacks T., Van Dyke T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78:1994;703-711.
44. Morin P.J., Kinzler K.W., Vogelstein B. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA. 93:1996;7950-7954.
45. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., Pandolfi P.P. Pml is essential for multiple apoptotic pathways. Nat Genet. 20:1998;266-271. The PML growth suppressor is required for Fas, TNF-α, ceramide, interferon, ionising radiation and caspase-dependent apoptosis. The mechanism by which PML mediates apoptosis is unknown but the PML-RARα fusion protein from acute promyelocytic leukemia blocks the apoptotic response to the various death-inducing signals possibly by acting as a dominant negative of PML.
46. McCurrach M.E., Connor T.M.F., Knudson C.M., Korsmeyer S.J., Lowe S.W. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA. 94:1997;2345-2349.
47. Yin C., Knudson C.M., Korsmeyer S.J., Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385:1997;637-640.
48. Polyak K., Xia Y., Zweier J.L., Kinzler K., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
49. Bennett M., Macdonald K., Chan S., Luzio J.P., Simari R., Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 282:1998;290-293. The authors show that induction of apoptosis by a tamoxifen-inducible p53-ER fusion protein in vascular smooth muscle cells occurs independently of transcription and translation. Apoptosis is associated with increased interaction of Fas and FADD and increased processing of the Fas through the Golgi to the cell surface. The authors have identified an important mechanism by which activation of p53 may sensitise cells to apoptosis; by promoting Fas receptor expression on the cell surface.
50. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W., Lowe S.W. Apaf-1 and caspase 9 in p53-dependent apoptosis and tumor inhibition. Science. 284:1999;156-159. Loss of Apaf-1 or caspase 9 blocks the ability of activated p53 to induce apoptosis following oncogene expression. Inactivation of Apaf-1 or caspase 9 also substitutes for p53 loss in tumorigenesis. Unlike loss of Bax, the effect of loss of either Apaf-1 or caspase 9 is complete in abolishing the ability of p53 to induce apoptosis. Apaf-1 and caspase 9 are not required for death induced by Fas or TNFα. The mechanism by which p53 induces the activity of Apaf-1 or caspase 9 is currently not understood.
51. Jurgensmeier J.M., Xie Z., Deveraux Q., Ellerby L., Bredesen D., Reed J.C. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA. 95:1998;4997-5002.
52. Juin P., Hueber A.O., Littlewood T., Evan G. c-Myc induced sensitisation to apoptosis is mediated through cytochrome c release. Genes Dev. 13:1999;1367-1381. Expression of the c-Myc oncogene in cells in a low-serum medium results in release of cyctochrome c into the cytosol in a manner that could be inhibited by the IGF-I survival factor. Blocking cyctochrome c release blocks Myc-induced apoptosis independently of p53 or Fas. Injection of cyctochrome c into the cytosol of cells sensitises those cells to apoptosis by other signals such as ionising radiation or Fas. The authors suggest that Myc sensitises cells to apoptosis by inducing release of cytochrome c.
53. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signalling via the ARF tumor suppressor regulates p53-dependent apoptosis. Genes Dev. 12:1998;2424-2433.
54. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
55. del Peso L., Gonzalez-Garcia M., Page C., Herrera R., Nunez G. Interleukin 3 induced phosphorylation of BAD through the protein kinase Akt. Science. 278:1997;687-689.
56. Cardone M.H., Roy N., Stennicke H., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., Reed J.C. Regulation of cell death protease caspase 9 by phosphorylation. Science. 282:1998;1318-1321. Cytochrome c induced cleavage of pro-caspase 9 is ineffective in cells over-expressing active Akt or Ras. Akt is shown to phosphorylate pro-caspase 9 in vitro and mutant forms of caspase 9 that could not be phosphorylated are resistant to the anti-apoptotic effects of Akt.
57. Romashkova J.A., Makarov S.S. NF-κB is a target of AKT in anti apoptotic PDGF signaling. Nature. 401:1999;86-90. Following mitogen stimulation, Akt activates IKK resulting in IκB degradation and activation of NF-κB. Nf-κB blocks apoptosis by inducing expression of anti-apoptotic IAP genes. Nf-κB is also involved in activating c-Myc expression.
58. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-κB activation by tumor necrosis factor requires the Akt serine-threonine kinase. Nature. 401:1999;82-85. Nf-κB is activated by inflammatory cytokines such as TNFα and this is also dependent on Akt phosphorylation of IKK. The effects of TNF on Nf-κB can be blocked by inhibitors of PI 3′kinase, dominant negative PI3′kinase and kinase dead Akt. Both NIK and Akt are required for Nf-κB activation in response to TNFα
59. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting Forkhead transcription factor. Cell. 96:1999;857-868. In response to survival factors, Akt phosphorylates members of the Forkhead family of transcription factors inducing the formation of a complex with 14-3-3 proteins and retention of Forkhead in the cytoplasm. Withdrawal of survival factor results in Forkhead hypo-phosphorylation and translocation to the nucleus where it induces the expression of genes such as Fas ligand.
60. Kops G.J.P.L., de Ruiter N.D., de Vries-Smits A.M.M., Powell D.R., Bos J.L., Burgering B.M.T. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 398:1999;630-634. Akt and other Ras-induced signaling molecules phosphorylate Forkhead family member AFX to block its transcriptional activity.
61. Hill L.L., Ouhtit A., Loughlin S.M., Kripke M.L., Ananthaswamy H.N., Owen-Schaub L.B. Fas ligand: a sensor for DNA damage critical in skin ancer etiology. Science. 285:1999;898-900.
62. Evan G., Littlewood T. A matter of life and death. Science. 281:1998;1317-1322.
63. Tan X., Wang J.Y.J. The caspase-RB connection in cell death. Trends Cell Biol. 8:1998;116-120.
64. Hsieh J-K., Chan F.S.G., O'Connor D.J., Mittnacht S., Zhong S., Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell. 3:1999;181-193.
65. Macleod K., Hu Y., Jacks T. Loss of Rb activates both p53-dependent and -independent cell death pathways in the developing mouse nervous system. EMBO J. 15:1996;6178-6188.
66. Samuelson A.V., Lowe S.W. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1a mutants unable to bind the RB-related proteins. Proc Natl Acad Sci USA. 94:1997;12094-12099.
67. Hueber A., Evan G.I. Traps to catch unwary oncogenes. Trends Genet. 14:1998;364-367.
68. -/- colon carcinoma. Science. 275:1997;1784-1787.
69. Rubinfeld B., Robbins P., El-Gamil M., Albert I., Porfiri E., Polakis P. Stabilisation of β-cateninby genetic defects in melanoma cell lines. Science. 275:1997;1790-1792.
70. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of cMyc as a target of the APC pathway. Science. 281:1998;1509-1512.
71. 1. This arrest could be overcome by expression of cyclin D1 from a heterologous promoter.
72. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of β-catenin-Tcf signaling in colon cancer by mutation in β-catenin or APC. Science. 275:1997;1787-1790.
73. Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J., Harper J.W. The SCFβ-TRCP-ubiquitin ligase complex associates specificially with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 13:1999;270-283. SCFβ mediates degradation of IκBα thereby activating the Nf-κB pathway which blocks apoptosis and promotes proliferation. SCFβ also mediates degradation of β-catenin suggesting an anti-proliferative function.
74. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localisation. Genes Dev. 12:1998;3499-3511. Phosphorylation of cyclin D1 on Thr286 promotes its proteolytic degradation and ensures that cyclin D1 levels in the cells remain responsive to mitogenic signaling. The authors show that glycogen synthase 3β can phosphorylate cyclin D1 in vitro. Cyclin D1 that cannot be phosphorylated remains nuclear and is not degraded.
75. Rubinfeld B., Albert I., Porfiri E., Fiol C., Munemitsu S., Polakis P. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science. 272:1996;1023-1026.
76. Matsumine A., Ogai A., Senda T., Okumura N., Satoh K., Baeg G., Kawahara T., Kobayashi S., Okada M., Toyoshima K., Akiyama T. Binding of APC to the human homolog of the Drosophila Discs Large tumor suppressor protein. Science. 272:1996;1020-1023.
77. Miller J.R., Moon R.T. Signal transduction through β-catenin and specificiation of cell fate during embryogenesis. Genes Dev. 10:1996;2527-2539.
78. Novak A., Hsu S.C., Leung-Hagesteijn C., Radeva G., Papkoff J., Montesano R., Roskelley C., Grosschedl R., Dedhar S. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and β-catenin signaling pathways. Proc Natl Acad Sci USA. 95:1998;4374-4379.
79. Delcommenne M., Tan C., Gray V., Rue L., Woodgett J., Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3β and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA. 95:1998;11211-11216. Integrin-linked kinase can phosphorylate both GSK-3β and Akt in response to extracellular matrix signaling. ILK acts to inhibit GSK-3β and activate Akt and would be predicted to promote proliferation and block apoptosis.
80. Rubinfeld B., Souza B., Albert I., Muller O., Chamberlain S.H., Masiarx F.R., Munemitsu S., Polakis P. Association of the APC gene product with β-catenin. Science. 262:1993;1731-1734.
81. Su L.K., Vogelstein B., Kinzler K.W. Association of the APC tumor suppressor protein with catenins. Science. 262:1993;1734-1737.
82. Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. E-cadherin germline mutations in familial gastric cancer. Nature. 392:1998;402-405.
83. Kaelin W.G.J. Many vessels, faulty gene. Nature. 399:1999;203-204.
84. Stebbins C.E., Kaelin W.G.J., Pavletich N.P. Structure of the VHL Elongin B complex: implications for VHL tumor suppressor function. Science. 284:1999;455-461. The authors resolve the crystal structure of VHL complexed to Elongin B and C. Tumor mutations in VHL were predicted to inhibit the VHL/Elongin C interaction. Furthermore, the structure revealed a high degree of homology between the SCF ubiquitin ligase conplex and the VHL/Elongin C/Elongin B complex.
85. 1-S transition: the SCF connection. Curr Opin Genet Dev. 8:1998;36-42.
86. ••] has identified a specific target of the VHL-Elongin-BC complex, the HIF-1a transcription factor.
87. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-276. In VHL-defective cells, the HIF1α subunit is stabilised and HIF1-mediated gene expression is activated in an oxygen-independent manner. The resoration of VHL function induces oxygen-dependent instability of HIF-1α. Vascular endothelial growth factor is positively regulated by HIF-1, suggesting a mechansism by which hypoxia might induce angiogenesis and explaining why VHL-negative tumors are highly vascularised.
88. Carmeliet P., Dor Y., Herbert J., Fukumura D., Brusselsmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P.et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature. 394:1998;485-490.
89. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 379:1996;88-91.
90. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilisation of wild-type p53 by hypoxia-inducible factor 1α Nature. 392:1998;405-408.
91. Gross-Mesilaty S., Reinstein E., Bercovich B., Tobias K.E., Schwartz A.L., Kahana C., Ciechanover A. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci USA. 95:1998;8058-8063.
92. Hateboer G., Kerkhoven R.M., Shvarts A., Bernards R., Beijersbergen R.L. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev. 10:1996;2960-2970.
93. Hofmann F., Martelli F., Livingston D.M., Wang Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiqutin-proteasome pathway. Genes Dev. 10:1996;2949-2959.
94. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Sal G., Chau V., Yew P.R., Draetta G.F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 268:1995;682-685.
95. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
96. Kubbutat M.H.G., Jones S.N., Vousden K.H. Regulation of p53 stability by mdm2. Nature. 387:1997;299-303.
97. Singer J.D., Gurian-West M., Clurman B., Roberts J.M. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev. 13:1999;2375-2387. The abundance of cyclin E is specifically regulated by the cullin-3 ubiquitin-protein ligase. Cullin-3 binds directly to free cyclin E, resulting in its ubiquitination and elimination by the proteasome. Inactivation of cullin-3 results in elevated levels of cyclin E and increased numbers of cells in S phase.
98. Gibson S., Tu S., Oyer R., Anderson S.M., Johnson G.L. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem. 274:1999;17612-17618. The authors show that stimulation of cells with EGF could protect them from Fas-induced killing. EGF protects cells from apoptosis by preventing Fas-induced caspase cleavage of Akt. Expression of activated Akt was sufficient to block Fas-induced death. These findings demonstrate that Akt is subject to regulation by caspases and that Akt mediates the survival functions of EGF.
99. Salghetti S.E., Kim S.Y., Tansey W.P. Destruction of Myc by ubiquitin mediated proteolysis: cancer associated and transforming mutations that stabilise Myc. EMBO J. 18:1999;717-726. Myc protein is stabilised by tumor-associated mutations in its transactivation domain at T58A. Increased Myc stablility would be expected to promote its transforming activity.
100. Sears R., Leone G., DeGregori J., Nevins J.R. Ras enhances Myc protein stability. Mol Cell. 3:1999;169-179. The half-life of c-Myc protein increases in growth factor stimulated cells in a manner dependent on the Ras/Raf/MAPK pathway. In quiescent cells, Myc is rapidly degraded by the proteasome. Phosphorylation of Myc by MAPK can occur in vitro and mutation of this MAPK site in Myc interferes with the ability of Myc to cooperate with Ras in transformation assays in vivo. Whether this phosphorylation or other phosphorylation events protect Myc from ubiquitination, remains to be seen.
101. Pause A., Lee S., Lonergan K.M., Klausner R.D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA. 95:1998;993-998.
102. Freed E., Lacey K.R., Huie P., Lyapina S.A., Deshaies R.J., Streans T., Jackson P.K. Components of an SCF ubiquitin ligase localise to the centrosome and regulate the centrosome duplication cycle. Genes Dev. 13:1999;2242-2257. SCF complexes associate with centrosomes at interphase and mitosis and purified centrosomes contain Skp1 and Cul1 proteins. SCF is required for centrosome separation, suggesting a regulatory role for proteolysis in chromosome separation and genome inegrity.
103. Cenciarelli C., De Santa F., Puri P.L., Mattei E., Ricci L., Bucci F., Felsani A., Caruso M. Critical role played by cyclin D3 in the MyoD mediated arrest of cell cycle during myoblast differentiation. Mol Cell Biol. 19:1999;5203-5217. Cyclin D3 is stabilised upon differentiation of myocytes by complex formation with hypophosphorylated pRb. Cyclin D3 upregulation and stability is inhibited by E1a. Conversely, over-expression of cyclin D3 blocks E1a-induced DNA synthesis suggesting a role for cyclin D3 in terminal cell cycle exit during differentiation.
104. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M. Inhibition of cell migration, spreading and focal adhesions by tumor suppressor PTEN. Science. 280:1998;1614-1617.
105. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:1995;785-789.
106. Fambrough D., McClure K., Kazlauskas A., Lander E.S. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping rather than independent sets of genes. Cell. 97:1999;727-741. Using DNA microarrays, the authors examined the expression of immediate-early genes (IEGs) induced
107. Fan S., Wang J., Yuan R., Ma Y., Meng Q., Erdos M.R., Pestell R.G., Yuan F., Auborn K.J., Goldberg I.D., Rosen E.M. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 284:1999;1354-1356. The breast cancer susceptibility gene product BRCA1 is shown to inhibit signaling by the ligand-activated estrogen receptor in transient transfection assays, suggesting a role in suppressing estrogen-dependent transcription during mammary epithelial proliferation.
108. He T-C., Chan T.A., Vogelstein B., Kinzler K.W. PPARδ is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell. 99:1999;335-345. The authors identified PPARδ as an APC-regulated gene by SAGE methodology and were able to confirm that induction of APC in colorectal cell lines repressed expression of PPARδ but not other members of the PPAR family. The inhibition of PPARδ by APC was mediated by β-catenin/Tcf-4 binding sites in the promoter of PPARδ. NSAIDS also inhibited PPARδ by interfering with the DNA-binding activity of PPARδ/RXRα dimers and over-expression of PPARδ could partially repress programmed cell death induced by NSAIDS. A role for PPAR receptors in regulating the growth of colonic epithelium has already been proposed [29] and the data presented here further support a key role for these transcriptional regulators in colorectal tumorigenesis. The critical targets of the PPARs in growth control remain to be identified but as factors regulated by the APC tumor suppressor gene, NSAIDS and dietary lipids, the function of PPARs requires great attention.